CompletedNot Applicable

Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism

China2,000 participantsStarted 2019-01-01

Plain-language summary

Patients with colorectal cancer (CRC) have a higher risk of both venous thromboembolism (VTE) and major bleeding (MB). Patients with CRC are underrepresented in the major trials examining treatment of cancer-associated VTE with anticoagulant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
✓. CRC patients with VTE treated with an anticoagulant (rivaroxaban or LMWH) for at least six months.

What they're measuring

recurrent VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE)

Timeframe: From the date of index VTE to VTE recurrence, assessed up to 12 months

Major Bleeding (MB)

Timeframe: From the date of index VTE to MB occurrence, assessed up to 12 months

Clinical Relevant Non Major Bleeding (CRNMB)

Timeframe: From the date of index VTE to CRNMB occurrence, assessed up to 12 months

Trial details

NCT IDNCT06440044

SponsorSixth Affiliated Hospital, Sun Yat-sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-16

View on ClinicalTrials.gov More Thrombosis, Venous trials